21-hydroxylase deficiency risk factors: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}}
{{Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}}
Please help WikiDoc by adding more content here. It's easy!  Click  [[Help:How to Edit a Page|here]] to learn about editing.
{{CMG}} {{AE}} {{AAM}}
 
==Overview==
The most potent risk factor in the development of 21-hydroxylase deficient congenital adrenal hyperplasia is [[Mutation]]s in the '''CYP21A2''' gene.
==Risk Factors==
[[Mutation]]s in the '''CYP21A2''' gene cause 21-hydroxylase deficient congenital adrenal hyperplasia.
== References ==
== References ==
{{Reflist|2}}
{{Reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Needs content]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Pediatrics]]
[[Category:Pediatrics]]

Revision as of 14:25, 4 September 2015

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

21-hydroxylase deficiency risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 21-hydroxylase deficiency risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 21-hydroxylase deficiency risk factors

CDC on 21-hydroxylase deficiency risk factors

21-hydroxylase deficiency risk factors in the news

Blogs on 21-hydroxylase deficiency risk factors

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Risk calculators and risk factors for 21-hydroxylase deficiency risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

The most potent risk factor in the development of 21-hydroxylase deficient congenital adrenal hyperplasia is Mutations in the CYP21A2 gene.

Risk Factors

Mutations in the CYP21A2 gene cause 21-hydroxylase deficient congenital adrenal hyperplasia.

References

Template:WikiDoc Sources